Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Glatz, M; Golestani, M; Kerl, H; Müllegger, RR.
Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients.
Arch Dermatol. 2006; 142(7):862-868
Doi: 10.1001/archderm.142.7.862
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Glatz Martin
- Muellegger Robert
- Co-Autor*innen der Med Uni Graz
- Kerl Helmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objectives: To investigate the kinetics of anti-Borrelia burgdorferi antibodies for a minimum of 1 year after antibiotic therapy in patients with erythema migrans (EM) and to correlate antibody titer kinetics with clinical variables. Design: Retrospective study of serial anti-B burgdorferi antibodies in correlation to clinical variables. Setting: University-based hospital. Patients: One hundred thirteen patients with EM. Interventions: Pretreatment and a median of 4 consecutive posttreatment serum samples from median follow-up of more than 400 days were simultaneously investigated for anti-B burgdorferi IgG and IgM antibodies. Semiquantitative titers were plotted to identify different groups of antibody kinetics. Individual patients were then stratified to those groups according to their antibody development. A statistical comparison of clinical and therapy-related characteristics among the serologic groups was performed. Results: Anti-B burgdorferi IgG and IgM antibody titers developed in 3 distinct courses: persistent positivity across follow-up (IgG: 12 patients, 11%; IgM: 14, 12%), persistent negativity (IgG: 63, 56%; IgM: 47, 42%), and decrease of a positive pretreatment titer to a negative titer approximately 5 months after therapy (IgG: 34, 30%; IgM: 49, 43%). Statistics revealed significant correlations only between persistent positive IgG titers and long disease duration or large EM lesions before therapy. Conclusions: Long duration or large size of EM before therapy correlates with persistence of a positive anti-B burgdorferi IgG antibody titer after therapy. Serologic profiles do not depend on the type or duration of therapy or the clinical course thereafter. Thus, antibody testing in the follow-up of patients with EM is inappropriate for the assessment of therapeutic response.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Amoxicillin - administration & dosage Amoxicillin - therapeutic use
- Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use
- Antibodies, Bacterial - blood
- Antibody Formation -
- Borrelia burgdorferi - immunology
- Ceftriaxone - administration & dosage Ceftriaxone - therapeutic use
- Child -
- Doxycycline - administration & dosage Doxycycline - analogs & derivatives Doxycycline - therapeutic use
- Enzyme-Linked Immunosorbent Assay -
- Erythema Chronicum Migrans - blood Erythema Chronicum Migrans - drug therapy Erythema Chronicum Migrans - immunology
- Female -
- Humans -
- Immunoglobulin G - immunology
- Immunoglobulin M - immunology
- Male -
- Middle Aged -
- Minocycline - administration & dosage Minocycline - therapeutic use
- Penicillin V - administration & dosage Penicillin V - therapeutic use
- Predictive Value of Tests -
- Retrospective Studies -